ALN-SOD
RNA / oligonucleotide
Evidence outlook
Early-stage evidence only
Phase 1 / first-in-human studies establish safety, tolerability, and dosing; they are not designed to demonstrate efficacy, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
Featured-trial selection for this indication is pending.
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 1/2 (1)
What this study did
Competitive landscape
Other SOD1 drugs
1 other tracked programme targets this mechanism, 1 of them ahead of this one.
This drug's own stage for Amyotrophic Lateral Sclerosis: Phase 1/2. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| ALN-SOD: this drug | Phase 1/2 | RNA / oligonucleotide | SOD1 | not yet graded | No reviewed efficacy summary in this indication | |
| Edaravone (Radicava ORS) | Approved | Small molecule | Reactive oxygen species (ROS) | Weak signal | Featured results are safety only in this race | |
| Tofersen (Qalsody) | Approved | RNA / oligonucleotide | SOD1 | Partial signal | No reviewed efficacy summary in this indication | |
| Masitinib | Phase 3 | Small molecule | KIT (c-Kit), also PDGFR and Lyn/Fyn kinases | not yet graded | No reviewed efficacy summary in this indication | |
| Ulefnersen | Phase 3 | RNA / oligonucleotide | FUS | Reliable signal | NCT04768972: FUSION (NCT04768972): ulefnersen met its primary endpoint, a joint rank (win-ratio style) analysis of time to death/permanent ventilation, time to rescue, and change in ALSFRS-R score to Day 505 vs placebo; p=0.0005. | |
| CB03-154 | Phase 2/3 | Small molecule | KCNQ2/3 (Kv7.2/7.3) potassium channel (opener) | not yet graded | No reviewed efficacy summary in this indication | |
| CNM-Au8 | Phase 2/3 | Nanoparticle | mitochondrial energy metabolism | not yet graded | No reviewed efficacy summary in this indication | |
| Ibudilast | Phase 2/3 | Small molecule | PDE4 and PDE10; macrophage migration inhibitory factor (MIF) | not yet graded | No reviewed efficacy summary in this indication | |
| Tazbentetol (SPG302) | Phase 2/3 | Small molecule | Dendritic spine density | Weak signal | Featured results are safety only in this race | |
| Dazucorilant | Phase 2 | Small molecule | Glucocorticoid receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Foralumab | Phase 2 | Monoclonal antibody | CD3 | not yet graded | No reviewed efficacy summary in this indication |
Compare side by side
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow ALN-SOD to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.